The landscape of sickle cell disease (SCD) treatment continues to evolve rapidly, with new disease-modifying therapies in development and potentially curative options on the horizon. [Source]

This Masterclass was moderated by Dr. Andrew Campbell (Director, Comprehensive Sickle Cell Disease Program, Children’s National Health System; Director of the Consortium for the Advancement of Sickle Cell Disease Research) and featured Dr. Lewis Hsu (Chief Medical Officer, SCDAA) and Dr. Donnell Ivy (Vice Chief Medical Officer, SCDAA).